Recent Progress of CircRNAs in Hematological Malignancies

Ya-Bin Cui, Lijie Wang, Jinhui Xu, Huijie Nan, Pei-Yao Yang, Jun-Wei Niu, Mingyue Shi, Yanliang BaiInternational Journal of Medical Sciences 2024 · DOI

This academic review, published in the International Journal of Medical Sciences (2024), provides a comprehensive synthesis of how circular RNAs (circRNAs)—once dismissed as "splicing noise"—have emerged as pivotal regulators in the landscape of blood cancers.

TL;DR

Circular RNAs (circRNAs) are highly stable, closed-loop molecules that act as "master regulators" in hematological malignancies by sponging up microRNAs and influencing gene expression. This review highlights their dual potential as ultra-stable diagnostic biomarkers and as a "frontier" for overcoming therapeutic resistance in diseases like leukemia and multiple myeloma.

What Problem Does This Paper Address?

Hematological malignancies (blood cancers) like Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) are notoriously difficult to treat due to their genetic complexity and the frequent development of drug resistance. While researchers have long focused on linear messenger RNAs (mRNAs), these are often unstable and easily degraded.

The authors address the need for more robust biomarkers and novel therapeutic targets. They explore the role of circRNAs—a unique class of non-coding RNAs that lack the "ends" (5' caps and 3' tails) found in linear RNA. This circular structure makes them incredibly resistant to the enzymes that usually break down RNA, allowing them to persist in the blood and bone marrow as functional signaling molecules.

Methods

As a comprehensive review, the authors synthesized findings from hundreds of primary research studies. The underlying research they analyzed typically utilizes:

  • Molecular Profiling: High-throughput sequencing (RNA-seq) and microarrays to identify which circRNAs are "upregulated" (overexpressed) or "downregulated" in cancer patients versus healthy controls.
  • Functional Assays: In vitro (cell culture) and in vivo (mouse model) experiments using siRNA knockdown or CRISPR-based overexpression to see how specific circRNAs affect tumor growth, cell cycle arrest, and apoptosis.
  • Bioinformatics: Mapping the "ceRNA (competitive endogenous RNA) networks" to determine which microRNAs a specific circRNA is "sponging" to prevent them from silencing target genes.

Datasets

While the review does not introduce a new standalone dataset, it aggregates data from numerous clinical cohorts, including:

  • Bone marrow and peripheral blood samples from hundreds of patients across AML, CML, ALL, CLL, and Multiple Myeloma.
  • Standardized cancer cell lines (e.g., HL-60 for AML, K562 for CML, and U266 for Multiple Myeloma).
  • Specific prognostic benchmarks, such as Area Under the Curve (AUC) values for diagnostic accuracy (e.g., circCDYL in Mantle Cell Lymphoma showed an impressive AUC of 0.856).

Key Insights and Ideas

  • The "Sponge" Mechanism: The most common role for circRNAs is acting as a "miRNA sponge." By binding to microRNAs, they prevent those microRNAs from reaching their intended targets, effectively "turning on" genes that would otherwise be silenced.
  • Fusion-Derived circRNAs: In Chronic Myeloid Leukemia (CML), the famous BCR-ABL1 gene fusion doesn't just produce a rogue protein; it can also generate unique "fusion circRNAs" (like F-circBA1) that actively promote cell survival and drug resistance.
  • Exosomal Messengers: circRNAs can be packaged into exosomes (tiny bubbles secreted by cells) to communicate with the tumor microenvironment. For example, in AML, exosomal circ_001264 can "reprogram" nearby macrophages to help the cancer evade the immune system.
  • Stability as a Superpower: Because circRNAs have half-lives exceeding 48 hours (compared to minutes or hours for many linear RNAs), they are ideal candidates for "liquid biopsies"—non-invasive blood tests that can track a patient's response to treatment in real-time.

Key Results

The paper categorizes dozens of circRNAs by their clinical impact:

  • Chemoresistance: In AML, circNPM1 and circPAN3 were found to drive resistance to standard drugs like Adriamycin.
  • Prognosis: High levels of circSLC25A13 in AML patients correlate significantly with poor overall survival (OS).
  • Therapeutic Sensitization: Silencing circ_0026652 in Multiple Myeloma cells was shown to restore sensitivity to Bortezomib, a common but often resisted treatment.
  • Diagnostic Accuracy: Several circRNAs (like circRNF220) can distinguish between different types of leukemia (e.g., AML vs. ALL) with high sensitivity and specificity, potentially aiding in faster, more accurate diagnoses.

Limitations and Future Work

Despite the excitement, the authors acknowledge several hurdles:

  1. Clinical Translation: Most of these findings are still in the laboratory stage. Moving from a "sponge" theory to a bedside treatment is a massive leap.
  2. Delivery Systems: We currently lack efficient ways to deliver circRNA-based drugs (or their inhibitors) specifically to cancer cells without affecting healthy tissue.
  3. Functional Complexity: While many circRNAs act as sponges, others may translate into small peptides or interact directly with proteins. This "functional diversity" is not yet fully understood.
  4. Standardization: There is a need for standardized protocols in detecting and quantifying circRNAs across different laboratories to ensure diagnostic results are reproducible.

The authors conclude that while the "frontier" is promising, the next decade must focus on the engineering challenges of targeted delivery and large-scale clinical validation.

Summary updated

Abstract

Circular RNAs (circRNAs) are now recognized as key regulators in the epigenetic control of genetic expression, being involved in a wide range of cellular activities such as proliferation, differentiation, and apoptosis. Their unique closed-loop structure endows them with stability and resistance to exonuclease degradation, making them not only key regulatory molecules within the cell but also promising biomarkers for disease diagnosis and prognosis, particularly in hematological malignancies. This review comprehensively explores the role of circRNAs in the pathogenesis, progression, and therapeutic resistance of common hematological malignancies. Furthermore, the review delves into the prognostic significance of circRNAs, underscoring their potential in predicting disease outcomes and treatment response. Given their extensive involvement in cancer biology, circRNAs present a frontier for novel therapeutic strategies.
BibTeX
@article{cui2024recent,
  author = {Ya-Bin Cui and Lijie Wang and Jinhui Xu and Huijie Nan and Pei-Yao Yang and Jun-Wei Niu and Mingyue Shi and Yanliang Bai},
  title = {{Recent Progress of CircRNAs in Hematological Malignancies}},
  journal = {International Journal of Medical Sciences},
  year = {2024},
  doi = {10.7150/ijms.98156},
}
Figure